AU2014369446C1 - Bicyclic heterocycle compounds and their uses in therapy - Google Patents

Bicyclic heterocycle compounds and their uses in therapy Download PDF

Info

Publication number
AU2014369446C1
AU2014369446C1 AU2014369446A AU2014369446A AU2014369446C1 AU 2014369446 C1 AU2014369446 C1 AU 2014369446C1 AU 2014369446 A AU2014369446 A AU 2014369446A AU 2014369446 A AU2014369446 A AU 2014369446A AU 2014369446 C1 AU2014369446 C1 AU 2014369446C1
Authority
AU
Australia
Prior art keywords
methyl
compound
pyridin
pyrrolo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014369446A
Other languages
English (en)
Other versions
AU2014369446B2 (en
AU2014369446A1 (en
Inventor
Ildiko Maria Buck
Gianni Chessari
James Edward Harvey DAY
Charlotte Mary Griffiths-Jones
Steven Howard
Christopher Norbert Johnson
Gordon Saxty
Emiliano TAMANINI
Nicola Elizabeth WILSHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1322755.8A external-priority patent/GB201322755D0/en
Priority claimed from GB201406986A external-priority patent/GB201406986D0/en
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of AU2014369446A1 publication Critical patent/AU2014369446A1/en
Application granted granted Critical
Publication of AU2014369446B2 publication Critical patent/AU2014369446B2/en
Priority to AU2019200840A priority Critical patent/AU2019200840C1/en
Publication of AU2014369446C1 publication Critical patent/AU2014369446C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
AU2014369446A 2013-12-20 2014-12-19 Bicyclic heterocycle compounds and their uses in therapy Active AU2014369446C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200840A AU2019200840C1 (en) 2013-12-20 2019-02-07 Bicyclic heterocycle compounds and their uses in therapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1322755.8 2013-12-20
GBGB1322755.8A GB201322755D0 (en) 2013-12-20 2013-12-20 Bicyclic heterocycle compounds and their uses in therapy
GB201406986A GB201406986D0 (en) 2014-04-17 2014-04-17 Bicyclic heterocycle compounds and their uses in therapy
GB1406986.8 2014-04-17
PCT/GB2014/053778 WO2015092420A1 (en) 2013-12-20 2014-12-19 Bicyclic heterocycle compounds and their uses in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200840A Division AU2019200840C1 (en) 2013-12-20 2019-02-07 Bicyclic heterocycle compounds and their uses in therapy

Publications (3)

Publication Number Publication Date
AU2014369446A1 AU2014369446A1 (en) 2016-06-02
AU2014369446B2 AU2014369446B2 (en) 2018-11-22
AU2014369446C1 true AU2014369446C1 (en) 2020-03-12

Family

ID=52134239

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014369446A Active AU2014369446C1 (en) 2013-12-20 2014-12-19 Bicyclic heterocycle compounds and their uses in therapy
AU2019200840A Active AU2019200840C1 (en) 2013-12-20 2019-02-07 Bicyclic heterocycle compounds and their uses in therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200840A Active AU2019200840C1 (en) 2013-12-20 2019-02-07 Bicyclic heterocycle compounds and their uses in therapy

Country Status (29)

Country Link
US (6) US9783538B2 (enExample)
EP (2) EP3083616B1 (enExample)
JP (3) JP6470756B2 (enExample)
KR (1) KR102408262B1 (enExample)
CN (3) CN105829310B (enExample)
AU (2) AU2014369446C1 (enExample)
BR (2) BR112016014561B1 (enExample)
CA (1) CA2933939C (enExample)
CY (1) CY1124436T1 (enExample)
DK (1) DK3083616T3 (enExample)
ES (1) ES2883289T3 (enExample)
HR (1) HRP20211406T1 (enExample)
HU (1) HUE056297T2 (enExample)
IL (1) IL246239B (enExample)
LT (1) LT3083616T (enExample)
MX (1) MX380469B (enExample)
MY (2) MY186311A (enExample)
NZ (2) NZ758528A (enExample)
PH (1) PH12016501139B1 (enExample)
PL (1) PL3083616T3 (enExample)
PT (1) PT3083616T (enExample)
RS (1) RS62301B1 (enExample)
RU (1) RU2696310C1 (enExample)
SA (1) SA516371360B1 (enExample)
SG (2) SG11201604795RA (enExample)
SI (1) SI3083616T1 (enExample)
SM (1) SMT202100497T1 (enExample)
TW (1) TWI649319B (enExample)
WO (1) WO2015092420A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN105829310B (zh) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
DK3380086T3 (da) 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
WO2017143449A1 (en) * 2016-02-24 2017-08-31 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP2019514878A (ja) 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｉｐｋ２阻害剤を含むコンジュゲート
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3468600A4 (en) 2016-06-10 2019-11-13 IO Therapeutics, Inc. RECEPTOR-ELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNOMODULATORS FOR CANCER IMMUNOTHERAPY
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
MX2020000467A (es) * 2017-07-13 2020-08-03 Io Therapeutics Inc Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer.
CN111148514A (zh) 2017-08-31 2020-05-12 Io治疗公司 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
US20220096436A1 (en) 2019-01-17 2022-03-31 Debiopharm International S.A. Combination product for the treatment of cancer
CA3130706A1 (en) 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CA3151770A1 (en) 2019-09-25 2021-04-01 Silvano BRIENZA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
ES3050095T3 (en) * 2020-05-04 2025-12-19 Taiho Pharmaceutical Co Ltd Methods for synthesizing anhydrous lactic acid
CN120247907A (zh) * 2020-05-04 2025-07-04 大塚制药株式会社 Iap拮抗剂化合物和中间体及其合成方法
WO2021244608A1 (en) * 2020-06-04 2021-12-09 Beigene, Ltd. Pyrido[2,3-b] [1,4] oxazines or tetrahydropyrido[2,3-b][1,4] oxazepines as iap antagonists
BR112023002457A2 (pt) * 2020-08-12 2023-05-02 Archer Daniels Midland Co Processo para purificar uma composição bruta compreendendo ácido 2,5-furanodicarboxílico, éster de dimetila (fdme)
US20230313313A1 (en) 2020-08-27 2023-10-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
JP2023541434A (ja) * 2020-09-14 2023-10-02 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体の標的化分解のための化合物の結晶性形態
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
TW202322822A (zh) 2021-08-20 2023-06-16 日商大塚製藥股份有限公司 組合醫藥
CA3234317A1 (en) 2021-10-22 2023-12-14 Wa Xian Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
EP4427747A4 (en) * 2021-11-05 2025-09-17 Haihe Biopharma Co Ltd SOLID DISPERSION, PREPARATION METHOD THEREOF AND SOLID FORMULATION CONTAINING IT
KR20240156407A (ko) 2022-03-04 2024-10-29 오츠카 세이야쿠 가부시키가이샤 Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법
TW202410919A (zh) 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5促效劑與iap拮抗劑之組合療法
CA3266274A1 (en) 2022-08-31 2024-03-07 Taiho Pharmaceutical Co., Ltd. Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用
CN116375700B (zh) * 2023-01-10 2024-12-17 中国科学院成都生物研究所 一种4-氮杂吲哚啉类化合物及其合成方法与应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
TW202510888A (zh) 2023-07-31 2025-03-16 日商大塚製藥股份有限公司 包含托利那泮(tolinapant)之醫藥組合物及包裝
WO2025235719A1 (en) * 2024-05-08 2025-11-13 Viiv Healthcare Company Dimeric smac mimetics useful in hiv therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143726A1 (en) * 2011-04-21 2012-10-26 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
TW218875B (enExample) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
DK0892780T3 (da) 1996-02-22 2003-03-03 Bristol Myers Squibb Pharma Co m-Amidinophenylanaloger som faktor Xa-inhibitorer
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU732863B2 (en) 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
HUP0100926A3 (en) 1998-02-26 2003-03-28 Neurogen Corp Branford Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists
NZ507204A (en) 1998-03-31 2003-12-19 Acadia Pharm Inc Substituted piperidine and piperazine derivatives having activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6608084B1 (en) 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2000055143A1 (en) 1999-03-17 2000-09-21 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003508509A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
US6790845B2 (en) 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
EP1498125A4 (en) 2002-04-24 2008-08-20 Takeda Pharmaceutical USE OF COMPOUNDS WITH CCR ANTAGONISM
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
WO2004078715A1 (ja) 2003-03-07 2004-09-16 Astellas Pharma Inc. ２，６－ジ置換スチリルを有する含窒素へテロ環誘導体
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
MXPA06001636A (es) 2003-08-13 2006-04-28 Amgen Inc Antagonista del receptor de la hormona concentradora de melanina.
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
PT1778718E (pt) 2004-07-02 2014-12-03 Genentech Inc Inibidores de iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PL1851200T3 (pl) 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
AU2006311101A1 (en) 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor Xa
AU2006340014B2 (en) 2005-12-19 2012-12-20 Genentech, Inc. Inhibitors of IAP
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
US20100016340A1 (en) 2006-04-25 2010-01-21 Astex Therapeutics Limited Pharmaceutical compounds
EP2049524A2 (en) 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CA2666112A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
CN101535273B (zh) 2006-12-07 2012-04-11 诺瓦提斯公司 治疗增生性疾病的6-氧代-1,6-二氢嘧啶-2-基化合物
US7691851B2 (en) 2007-03-07 2010-04-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CN101827848B (zh) 2007-08-08 2012-11-07 葛兰素史密丝克莱恩有限责任公司 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
WO2009067233A1 (en) 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
MX2010007948A (es) 2008-01-24 2010-10-04 Tetralogic Pharm Corp Inhibidores de proteinas de apoptosis.
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
CA2763638A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
AU2012319188B2 (en) 2011-10-03 2016-11-24 Sloan-Kettering Institute For Cancer Research Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
ES2802251T3 (es) 2012-01-06 2021-01-18 Novartis Ag Compuestos heterocíclicos y métodos para su uso
GB201218864D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
CN105829310B (zh) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
CA2935944A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
CN120247907A (zh) 2020-05-04 2025-07-04 大塚制药株式会社 Iap拮抗剂化合物和中间体及其合成方法
ES3050095T3 (en) 2020-05-04 2025-12-19 Taiho Pharmaceutical Co Ltd Methods for synthesizing anhydrous lactic acid
KR20240156407A (ko) 2022-03-04 2024-10-29 오츠카 세이야쿠 가부시키가이샤 Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법
CA3266274A1 (en) 2022-08-31 2024-03-07 Taiho Pharmaceutical Co., Ltd. Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143726A1 (en) * 2011-04-21 2012-10-26 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Also Published As

Publication number Publication date
WO2015092420A1 (en) 2015-06-25
RU2696310C1 (ru) 2019-08-01
US20230227450A1 (en) 2023-07-20
SMT202100497T1 (it) 2021-09-14
EP3686200A3 (en) 2020-09-09
JP2017500338A (ja) 2017-01-05
PL3083616T3 (pl) 2021-12-06
JP6470756B2 (ja) 2019-02-13
AU2019200840B2 (en) 2020-05-28
KR102408262B1 (ko) 2022-06-10
MX2016008131A (es) 2016-09-16
CA2933939A1 (en) 2015-06-25
SI3083616T1 (sl) 2021-12-31
ES2883289T3 (es) 2021-12-07
MY186311A (en) 2021-07-08
IL246239A0 (en) 2016-08-02
RS62301B1 (sr) 2021-09-30
JP7110279B2 (ja) 2022-08-01
US20170029419A1 (en) 2017-02-02
LT3083616T (lt) 2021-09-10
US12202828B2 (en) 2025-01-21
AU2014369446B2 (en) 2018-11-22
BR112016014561B1 (pt) 2022-10-18
IL246239B (en) 2019-08-29
MY193649A (en) 2022-10-21
KR20160095160A (ko) 2016-08-10
MX380469B (es) 2025-03-12
US20220204503A1 (en) 2022-06-30
JP6735369B2 (ja) 2020-08-05
US9783538B2 (en) 2017-10-10
BR122022015241B1 (pt) 2023-09-26
DK3083616T3 (da) 2021-08-30
CY1124436T1 (el) 2022-07-22
JP2019070030A (ja) 2019-05-09
EP3686200A2 (en) 2020-07-29
TW201609724A (zh) 2016-03-16
EP3083616B1 (en) 2021-06-09
SG11201604795RA (en) 2016-07-28
AU2019200840A1 (en) 2019-02-28
CN115368356B (zh) 2025-05-09
SA516371360B1 (ar) 2019-02-10
CN109336883B (zh) 2022-06-14
RU2016129472A (ru) 2018-01-25
US11643410B2 (en) 2023-05-09
AU2019200840C1 (en) 2021-03-25
US20200325134A1 (en) 2020-10-15
CN115368356A (zh) 2022-11-22
US20180065959A1 (en) 2018-03-08
CN105829310B (zh) 2019-04-12
JP2020183409A (ja) 2020-11-12
NZ758528A (en) 2022-05-27
TWI649319B (zh) 2019-02-01
US10618895B2 (en) 2020-04-14
EP3083616A1 (en) 2016-10-26
PH12016501139A1 (en) 2016-07-18
CA2933939C (en) 2021-03-16
HUE056297T2 (hu) 2022-02-28
US20250296930A1 (en) 2025-09-25
BR112016014561A2 (enExample) 2017-08-08
HRP20211406T1 (hr) 2021-12-10
NZ719905A (en) 2019-10-25
CN109336883A (zh) 2019-02-15
PT3083616T (pt) 2021-08-12
SG10201808102WA (en) 2018-10-30
PH12016501139B1 (en) 2016-07-18
US11225476B2 (en) 2022-01-18
CN105829310A (zh) 2016-08-03
AU2014369446A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US12202828B2 (en) Bicyclic heterocycle compounds and their uses in therapy
EP2909196B1 (en) Bicyclic heterocycle compounds and their uses in therapy
HK40033709A (en) Bicyclic heterocycle compounds and their uses in therapy
HK40084234A (en) Bicyclic heterocycle compounds and their uses in therapy
HK40084234B (zh) 双环杂环化合物及其治疗用途
HK1230598B (en) Bicyclic heterocycle compounds and their uses in therapy
HK1262092B (en) Bicyclic heterocycle compounds and their uses in therapy
HK1262092A1 (en) Bicyclic heterocycle compounds and their uses in therapy

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHESSARI, GIANNI; JOHNSON, CHRISTOPHER NORBERT; HOWARD, STEVEN; DAY, JAMES EDWARD HARVEY; BUCK, ILDIKO MARIA; GRIFFITHS-JONES, CHARLOTTE MARY; SAXTY, GORDON; TAMANINI, EMILIANO AND WILSHER, NICOLA ELIZABETH

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 OCT 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 23 OCT 2019